RÉSUMÉ
BACKGROUND AND OBJECTIVES: The 9-valent human papillomavirus (9vHPV) vaccine Phase III immunogenicity study in 9- to 15-year-old boys and girls was extended to assess immunogenicity and effectiveness through 10 years after the last vaccine dose (NCT00943722). METHODS: Boys (n = 301) and girls (n = 971) who received three 9vHPV vaccine doses in the base study (day 1, months 2 and 6) enrolled in the extension. Serum was collected through month 126 for antibody assessments by competitive Luminex immunoassay and immunoglobulin G-Luminex immunoassay. For effectiveness analysis starting at age 16 years, genital swabs were collected (to assess HPV DNA by polymerase chain reaction) and external genital examinations conducted every 6 months. Primary analyses were conducted in per-protocol populations. RESULTS: Geometric mean antibody titers peaked around month 7, decreased sharply between months 7 and 12, then gradually through month 126. Seropositivity rates remained ≥81% by competitive Luminex immunoassay and ≥95% by immunoglobin G-Luminex immunoassay at month 126 for each 9vHPV vaccine type. After up to 11.0 (median 10.0) years of follow-up postdose 3, there were no cases of HPV6/11/16/18/31/33/45/52/58-related high-grade intraepithelial neoplasia or condyloma in males or females. Incidence rates of HPV6/11/16/18/31/33/45/52/58-related 6-month persistent infection in males and females were low (54.6 and 52.4 per 10000 person-years, respectively) and within ranges expected in vaccinated cohorts, based on previous human papillomavirus vaccine efficacy trials. CONCLUSIONS: The 9vHPV vaccine demonstrated sustained immunogenicity and effectiveness through â¼10 years post 3 doses of 9vHPV vaccination of boys and girls aged 9 to 15 years.
RÉSUMÉ
BACKGROUND: Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types 6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16-26â¯years of age. We present a phase 3 immunogenicity and safety study of the 9vHPV vaccine in women 27-45 versus 16-26â¯years of age. METHODS: This international, open-label study (NCT03158220) was conducted in women 16-45â¯years of age. Participants (16-26â¯years, nâ¯=â¯570 and 27-45â¯years, nâ¯=â¯642) received a three-dose 9vHPV vaccination regimen (day 1, month 2, month 6). Month 7 geometric mean titers (GMTs) and seroconversion percentages to anti-HPV 6/11/16/18/31/33/45/52/58 were assessed. Participants were followed for safety throughout the study. RESULTS: At month 7, anti-HPV 6/11/16/18/31/33/45/52/58 GMTs in women 27-45â¯years were compared to those in women 16-26â¯years of age. The primary hypothesis of non-inferiority of anti-HPV 16/18/31/33/45/52/58 GMTs in older versus younger women was met. The lower bound of the GMT ratio 95% confidence interval (27-45â¯years to 16-26â¯years) was 0.60-0.67 depending on HPV type, exceeding the non-inferiority margin of 0.5 for all HPV types. Month 7 seroconversion percentages in women 27-45â¯years of age were >99% for all HPV types. Injection-site and vaccine-related systemic adverse events (AEs) were observed in 87.5% and 25.1% of women 16-26â¯years, and 85.2% and 24.1% of women 27-45â¯years of age, respectively; no vaccine-related serious AEs were reported and no deaths occurred during the study. CONCLUSIONS: The 9vHPV vaccine elicited non-inferior anti-HPV GMTs in women 27-45â¯years compared with women 16-26â¯years of age for HPV 16/18/31/33/45/52/58. The vaccine was generally well tolerated with a similar AE profile across the age groups. These data support bridging 9vHPV vaccine efficacy findings in women 16-26â¯years to women 27-45â¯years of age. Clinical trial registration NCT03158220.
Sujet(s)
Infections à papillomavirus , Vaccins contre les papillomavirus , Adolescent , Adulte , Sujet âgé , Anticorps antiviraux , Femelle , Papillomavirus humain de type 16 , Papillomavirus humain de type 18 , Humains , Immunogénicité des vaccins , Infections à papillomavirus/prévention et contrôle , Vaccins contre les papillomavirus/effets indésirables , Jeune adulteRÉSUMÉ
BACKGROUND: The nine-valent human papillomavirus (9vHPV) vaccine protects against infection and disease related to HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The pivotal 36-month Phase III immunogenicity study of 9vHPV vaccine in 9- to 15-year-old girls and boys was extended to assess long-term immunogenicity and effectiveness through approximately 10 years after vaccination. We describe results of an interim analysis based on approximately 8 years of follow-up after vaccination. METHODS: Participants aged 9-15 years who received three doses of 9vHPV vaccine (at day 1, month 2, and month 6) in the base study and consented to follow-up were enrolled in the long-term follow-up study extension (N = 1272 [females, n = 971; males, n = 301]). Serum was collected at months 66 and 90 to assess antibody responses. For effectiveness analysis, genital swabs were collected (to assess HPV DNA by polymerase chain reaction [PCR]) and external genital examination was conducted (to detect external genital lesions) every 6 months starting when the participant reached 16 years of age. Cervical cytology tests were conducted annually when female participants reached 21 years of age; participants with cytological abnormalities were triaged to colposcopy based on a protocol-specified algorithm. External genital and cervical biopsies of abnormal lesions were performed, and histological diagnoses were adjudicated by a pathology panel. Specimens were tested by PCR to detect HPV DNA. RESULTS: Geometric mean titers for each 9vHPV vaccine HPV type peaked around month 7 and gradually decreased through month 90. Seropositivity rates remained >90% through month 90 for each of the 9vHPV vaccine types by HPV immunoglobulin Luminex Immunoassay. No cases of HPV6/11/16/18/31/33/45/52/58-related high-grade intraepithelial neoplasia or genital warts were observed in the per-protocol population (n = 1107) based on a maximum follow-up of 8.2 years (median 7.6 years) post-Dose 3. Incidence rates of HPV6/11/16/18/31/33/45/52/58-related 6-month persistent infection in females and males were 49.2 and 37.3 per 10,000 person-years, respectively, which were within ranges expected in vaccinated cohorts. There were no vaccine-related SAEs or deaths during the period covered by this interim analysis. CONCLUSIONS: The 9vHPV vaccine provided sustained immunogenicity and durable effectiveness through approximately 7 and 8 years, respectively, following vaccination of girls and boys aged 9-15 years.
Sujet(s)
Anticorps antiviraux/sang , Immunogénicité des vaccins , Papillomaviridae/immunologie , Infections à papillomavirus/prévention et contrôle , Vaccins contre les papillomavirus/immunologie , Adolescent , Enfant , Femelle , Études de suivi , Humains , Mâle , Infections à papillomavirus/immunologie , Vaccins contre les papillomavirus/administration et posologie , Vaccins contre les papillomavirus/classification , Facteurs temps , Vaccination/statistiques et données numériquesRÉSUMÉ
BACKGROUND: We evaluated an inactivated quadrivalent influenza vaccine (IIV4) in children 6-35 months of age in a phase III, observer-blind trial. METHODS: The aim of this analysis was to estimate vaccine efficacy (VE) in preventing laboratory-confirmed influenza in each of 5 independent seasonal cohorts (2011-2014), as well as vaccine impact on healthcare utilization in 3 study regions (Europe/Mediterranean, Asia-Pacific and Central America). Healthy children were randomized 1:1 to IIV4 or control vaccines. VE was estimated against influenza confirmed by reverse transcription polymerase chain reaction on nasal swabs. Cultured isolates were characterized as antigenically matched/mismatched to vaccine strains. RESULTS: The total vaccinated cohort included 12,018 children (N = 1777, 2526, 1564, 1501 and 4650 in cohorts 1-5, respectively). For reverse transcription polymerase chain reaction confirmed influenza of any severity (all strains combined), VE in cohorts 1-5 was 57.8%, 52.9%, 73.4%, 30.3% and 41.4%, respectively, with the lower limit of the 95% confidence interval >0 for all estimates. The proportion of vaccine match for all strains combined in each cohort was 0.9%, 79.3%, 72.5%, 24.1% and 28.6%, respectively. Antibiotic use associated with influenza illness was reduced with IIV4 by 71% in Europe, 36% in Asia Pacific and 59% in Central America. CONCLUSIONS: IIV4 prevented influenza in children 6-35 months of age in each of 5 separate influenza seasons in diverse geographical regions. A possible interaction between VE, degree of vaccine match and socioeconomic status was observed. The IIV4 attenuated the severity of breakthrough influenza illness and reduced healthcare utilization, particularly antibiotic use.
Sujet(s)
Vaccins antigrippaux/immunologie , Grippe humaine/épidémiologie , Grippe humaine/prévention et contrôle , Acceptation des soins par les patients , Vaccins inactivés/immunologie , Femelle , Géographie médicale , Humains , Virus de la grippe A/génétique , Virus de la grippe A/immunologie , Virus influenza B/génétique , Virus influenza B/immunologie , Vaccins antigrippaux/administration et posologie , Mâle , , Surveillance de la santé publique , Saisons , Vaccins inactivés/administration et posologieRÉSUMÉ
BACKGROUND: In an exploratory analysis of an inactivated quadrivalent influenza vaccine (IIV4) trial in children 6-35 months without risk factors for influenza, we evaluated clinical presentation of influenza illness and vaccine impact on health outcomes. METHODS: This phase III trial was conducted in 13 geographically diverse countries across 5 influenza seasons (2011-2014). Children were randomized 1:1 to IIV4 or control. Active surveillance was performed for influenza-like episodes (ILE); influenza was confirmed by reverse transcription polymerase chain reaction (RT-PCR). The total vaccinated cohort was evaluated (N = 12,018). RESULTS: 5702 children experienced ≥1 ILE; 356 (IIV4 group) and 693 (control group) children had RT-PCR-confirmed influenza. Prevalence of ILE was similar in RT-PCR-positive and RT-PCR-negative cases regardless of vaccination. Breakthrough influenza illness was attenuated in children vaccinated with IIV4; moderate-to-severe illness was 41% less likely to be reported in the IIV4 group than the control group [crude odds ratio: 0.59 (95% confidence intervals: 0.44-0.77)]. Furthermore, fever >39°C was 46% less frequent following vaccination with IIV4 than with control [crude odds ratio: 0.54 (95% confidence intervals: 0.39-0.75)] in children with breakthrough illness. Health outcome analysis showed that, each year, IIV4 would prevent 54 influenza cases per 1000 children and 19 children would need to be vaccinated to prevent 1 new influenza case. CONCLUSIONS: In addition to preventing influenza in 50% of participants, IIV4 attenuated illness severity and disease burden in children who had a breakthrough influenza episode despite vaccination.
Sujet(s)
Vaccins antigrippaux/immunologie , Grippe humaine/épidémiologie , Grippe humaine/prévention et contrôle , Enfant d'âge préscolaire , Femelle , Hospitalisation , Humains , Nourrisson , Vaccins antigrippaux/administration et posologie , Grippe humaine/diagnostic , Mâle , Odds ratio , Prévalence , Modèles des risques proportionnels , Surveillance de la santé publique , Indice de gravité de la maladie , Évaluation des symptômes , Vaccination , Vaccins inactivés/administration et posologie , Vaccins inactivés/immunologieRÉSUMÉ
BACKGROUND: It has not yet been demonstrated whether 2 doses of inactivated quadrivalent influenza vaccine (IIV4) prime a booster response in infants. We evaluated the anamnestic immune response to an IIV4 in children 17-48 months of age. METHODS: Children were randomized to 2 doses of IIV4 or control in the primary phase III study (NCT01439360). One year later, in an open-label revaccination extension study (NCT01702454), a subset of children who received IIV4 in the primary study (primed group) received 1 IIV4 dose and children who received control in the primary study (unprimed) received 2 IIV4 doses 28 days apart. The primary objective was to evaluate hemagglutination inhibition (HI) antibody titers 7 days after first IIV4 vaccination in the per-protocol cohort (N = 224 primed; N = 209 unprimed). Neutralizing and antineuraminidase antibodies were also measured. Safety was analyzed in the total vaccinated cohort (N = 241 primed; N = 229 unprimed). RESULTS: An anamnestic response was observed in primed children relative to unprimed controls, measured by age-adjusted geometric mean HI titer ratios against strains homologous (A/H1N1: 9.0; B/Victoria: 3.9) and heterologous (A/H3N2: 2.7; B/Yamagata: 6.7) to those in the primary vaccination series. The anamnestic response in primed children included increases in neutralizing antibodies (mean geometric increase: 5.0-10.6) and antineuraminidase antibodies (4.9-8.8). No serious adverse events related to vaccination were reported. CONCLUSIONS: In this study, 2-dose priming with IIV4 induced immune memory that was recalled with 1-dose IIV4 the following year to boost HI, antineuraminidase and neutralizing antibodies, even though the IIV4 strain composition partially changed.
Sujet(s)
Mémoire immunologique , Vaccins antigrippaux/effets indésirables , Vaccins antigrippaux/immunologie , Grippe humaine/prévention et contrôle , Anticorps neutralisants/sang , Anticorps antiviraux/sang , Enfant d'âge préscolaire , Effets secondaires indésirables des médicaments/épidémiologie , Effets secondaires indésirables des médicaments/anatomopathologie , Femelle , Tests d'inhibition de l'hémagglutination , Humains , Nourrisson , Vaccins antigrippaux/administration et posologie , Mâle , Tests de neutralisation , Vaccins inactivés/administration et posologie , Vaccins inactivés/effets indésirables , Vaccins inactivés/immunologieRÉSUMÉ
BACKGROUND: Despite the importance of vaccinating children younger than 5 years, few studies evaluating vaccine prevention of influenza have been reported in this age group. We evaluated efficacy of an inactivated quadrivalent influenza vaccine (IIV4) in children aged 6-35 months. METHODS: In this phase 3, observer-blinded, multinational trial, healthy children from 13 countries in Europe, Central America, and Asia were recruited in five independent cohorts, each in a different influenza season. Participants were randomly assigned (1:1) to either IIV4 (15 µg haemagglutinin antigen per strain per 0·5 mL dose; a single dose on day 0 for vaccine-primed children, and two doses, on days 0 and 28, for vaccine-unprimed children) or to one or two doses of a non-influenza control vaccine. Primary endpoints were moderate-to-severe influenza or all influenza (irrespective of disease severity) confirmed by RT-PCR on nasal swabs. Cultured isolates were further characterised as antigenically matched or mismatched to vaccine strains. Efficacy was assessed in the per-protocol cohort and total vaccinated cohort (time-to-event analysis), and safety was assessed in the total vaccinated cohort. FINDINGS: Between Oct 1, 2011, and Dec 31, 2014, 12â018 children were recruited into the total vaccinated cohort (6006 children in the IIV4 group and 6012 children in the control group). 356 (6%) children in the IIV4 group and 693 (12%) children in the control group had at least one case of RT-PCR-confirmed influenza. Of these 1049 influenza strains, 138 (13%) were A/H1N1, 529 (50%) were A/H3N2, 69 (7%) were B/Victoria, and 316 (30%) were B/Yamagata. Overall, 539 (64%) of 848 antigenically characterised isolates were vaccine-mismatched (16 [15%] of 105 for A/H1N1; 368 [97%] of 378 for A/H3N2; 54 [86%] of 63 for B/Victoria; 101 [33%] of 302 for B/Yamagata). Vaccine efficacy was 63% (97·5% CI 52-72) against moderate-to-severe influenza and 50% (42-57) against all influenza in the per-protocol cohort, and 64% (53-73) against moderate-to-severe influenza and 50% (42-57) against all influenza in the total vaccinated cohort. There were no clinically meaningful safety differences between IIV4 and control. INTERPRETATION: IIV4 prevented influenza A and B in children aged 6-35 months despite high levels of vaccine mismatch. Vaccine efficacy was highest against moderate-to-severe disease, which is the most clinically important endpoint associated with greatest burden. FUNDING: GlaxoSmithKline Biologicals SA.
Sujet(s)
Vaccins antigrippaux , Grippe humaine/prévention et contrôle , Enfant d'âge préscolaire , Femelle , Humains , Nourrisson , Grippe humaine/épidémiologie , Internationalité , Mâle , Saisons , Méthode en simple aveugleRÉSUMÉ
OBJECTIVE: To investigate the effectiveness and safety of the homeopathic product SilAtro-5-90 in recurrent tonsillitis. METHODS: In this international, pragmatic, controlled clinical trial, 256 patients (6-60 years) with moderate recurrent tonsillitis were randomized to receive either SilAtro-5-90 in addition to standard symptomatic treatment, or to receive standard treatment only. The primary outcome was the mean time period between consecutive acute throat infections (ATI) within 1 year (analyzed via repeated events analysis). RESULTS: During the evaluation year, the risk of getting an ATI was significantly lower (hazard ratio: 0.45, proportional means model, p = 0.0002, ITT) with SilAtro-5-90 compared to control. Tonsillitis-specific symptoms were significantly reduced (p < 0.0001, ITT) and the need of antibiotics to treat acute throat infections (p = 0.0008; ITT) decreased. 3 non-serious adverse drug reactions were reported for SilAtro-5-90. CONCLUSIONS: An integrative treatment approach where SilAtro-5-90 is given alongside mainstream symptomatic treatment may bring therapeutic benefit to patients suffering from recurrent tonsillitis. TRIAL REGISTRATION: ISRCTN registry: Registration number ISRCTN19016626, registered 23 January 2013.
Sujet(s)
Homéopathie , Matière médicale/usage thérapeutique , Amygdalite/traitement médicamenteux , Adolescent , Adulte , Antibactériens/usage thérapeutique , Enfant , Communication , Femelle , Humains , Mâle , Adulte d'âge moyen , Pharyngite , Récidive , Résultat thérapeutique , Jeune adulteRÉSUMÉ
BACKGROUND AND OBJECTIVE: Malnourishment can be caused by either a lack of food or an excess of low-nutrient foods. Due to several factors, this predisposes children to academic failure. The objective of this study is to estimate the prevalence of school children with eating problems, study their nutrition level, food quality in the diet, and level of physical activity. MATERIAL AND METHODS: The study involved the school children between 3 months and 16.5 years of age in the municipalities of Centelles, Hostalets de Balenyà and Sant Martí de Centelles. Personal, age, nutrition and physical activity data were collected for the descriptive and bivariate analyses. RESULTS: A total of 1,374 children were included, of which 122 were under 3 years of age (8.9%). Obesity was recorded in 2.5%, while 17.2, 15.6 and 64.8% were overweight, underweight and of normal weight, respectively. The remaining 1,252 children were over 3 years of age (91.1%), and obesity was recorded in 8.1%, while 26.1, 11.0 and 62.9% were overweight, underweight and of normal weight, respectively. Adherence to the Mediterranean diet decreased significantly with increasing age. The maintenance of body weight was significantly correlated to the consumption of carbohydrates for breakfast before going to school, daily fruit consumption, and not having a need for care from the social services. The differences in physical activity and a sedentary lifestyle proved significant between males and females. CONCLUSION: Being underweight and overweight are factors related to eating habits and dependency upon the social services.
Sujet(s)
Troubles nutritionnels de l'enfant/épidémiologie , Exercice physique , Comportement alimentaire , Malnutrition/épidémiologie , Enquêtes nutritionnelles , Obésité pédiatrique/épidémiologie , Étudiants/statistiques et données numériques , Adolescent , Facteurs âges , Anthropométrie , Enfant , Enfant d'âge préscolaire , Régime méditerranéen , Hydrates de carbone alimentaires , Femelle , Fruit , Humains , Nourrisson , Mâle , État nutritionnel , Mode de vie sédentaire , Facteurs sexuels , Services sociaux et travail social (activité)/statistiques et données numériques , Espagne , Maigreur/épidémiologie , LégumesRÉSUMÉ
Antecedentes y objetivo: La malnutrición puede deberse tanto a la falta de alimentos como al exceso de alimentos poco nutritivos. Ello predispone al niño, por diversos factores, a un fracaso escolar. El objetivo de este estudio es estimar la prevalencia de niños escolarizados con dificultades alimentarias, estudiar el grado de nutrición, la calidad alimentaria de la dieta y el grado de actividad física. Material y métodos: Se estudió la población escolarizada de las poblaciones de Centelles, Hostalets de Balenyà y Sant Martí de Centelles, de 3 meses a 16,5 años. Se recogieron datos personales, antropométricos, nutricionales y de actividad física para la valoración por análisis descriptivo y bivariante. Resultados: Se estudiaron 1.374 niños, 122 menores de 3 años (8,9%), observándose obesidad en el 2,5%, sobrepeso en el 17,2%, infrapeso en el 15,6% y normopeso en el 64,8% de la muestra, y 1.252 mayores de 3 años (91,1%), observándose un 62,9% de normopeso, un 11,0% de infrapeso y un 26,1% de exceso de peso, del cual un 8,1% se trataba de obesidad. La adherencia a la dieta mediterránea se reduce significativamente con la edad. Se observa una relación significativa para el mantenimiento de un peso corporal el consumo de hidratos de carbono para desayunar antes de ir a la escuela, consumir fruta diariamente y no precisar atención de los servicios sociales. Es significativa la diferencia de actividad física y sedentarismo entre sexos. Conclusión: El infrapeso y el exceso de peso son factores relacionados con los hábitos alimentarios y la dependencia de los servicios sociales (AU)
Background and objective: Malnourishment can be caused by either a lack of food or an excess of low-nutrient foods. Due to several factors, this predisposes children to academic failure. The objective of this study is to estimate the prevalence of school children with eating problems, study their nutrition level, food quality in the diet, and level of physical activity. Material and methods: The study involved the school children between 3 months and 16.5 years of age in the municipalities of Centelles, Hostalets de Balenyà and Sant Martí de Centelles. Personal, age, nutrition and physical activity data were collected for the descriptive and bivariate analyses. Results: A total of 1,374 children were included, of which 122 were under 3 years of age (8.9%). Obesity was recorded in 2.5%, while 17.2, 15.6 and 64.8% were overweight, underweight and of normal weight, respectively. The remaining 1,252 children were over 3 years of age (91.1%), and obesity was recorded in 8.1%, while 26.1, 11.0 and 62.9% were overweight, underweight and of normal weight, respectively. Adherence to the Mediterranean diet decreased significantly with increasing age. The maintenance of body weight was significantly correlated to the consumption of carbohydrates for breakfast before going to school, daily fruit consumption, and not having a need for care from the social services. The differences in physical activity and a sedentary lifestyle proved significant between males and females. Conclusion: Being underweight and overweight are factors related to eating habits and dependency upon the social services (AU)
Sujet(s)
Humains , Mâle , Femelle , Enfant , État nutritionnel , Comportement alimentaire , Exercice physique , Malnutrition/épidémiologie , Surpoids/complications , Obésité/complications , Régime méditerranéen , Anthropométrie/méthodesRÉSUMÉ
Importance: Human papillomavirus (HPV) infections cause anogenital cancers and warts. The 9-valent HPV vaccine provides protection against 7 high-risk types of HPV responsible for 90% of cervical cancers and 2 other HPV types accounting for 90% of genital warts. Objective: To determine whether HPV type-specific antibody responses would be noninferior among girls and boys aged 9 to 14 years after receiving 2 doses of the 9-valent HPV vaccine compared with adolescent girls and young women aged 16 to 26 years receiving 3 doses. Design, Setting, and Participants: Open-label, noninferiority, immunogenicity trial conducted at 52 ambulatory care sites in 15 countries. The study was initiated on December 16, 2013, with the last participant visit for this report on June 19, 2015. Five cohorts were enrolled: (1) girls aged 9 to 14 years to receive 2 doses 6 months apart (n = 301); (2) boys aged 9 to 14 years to receive 2 doses 6 months apart (n = 301); (3) girls and boys aged 9 to 14 years to receive 2 doses 12 months apart (n = 301); (4) girls aged 9 to 14 years to receive 3 doses over 6 months (n = 301); and (5) a control group of adolescent girls and young women aged 16 to 26 years to receive 3 doses over 6 months (n = 314). Interventions: Two doses of the 9-valent HPV vaccine administered 6 or 12 months apart or 3 doses administered over 6 months. Main Outcomes and Measures: The primary end point was prespecified as the antibody response against each HPV type assessed 1 month after the last dose using a competitive immunoassay. Each of the three 2-dose regimens was compared with the standard 3-dose schedule in adolescent girls and young women using a noninferiority margin of 0.67 for the ratio of the antibody geometric mean titers. Results: Of the 1518 participants (753 girls [mean age, 11.4 years]; 451 boys [mean age, 11.5 years]; and 314 adolescent girls and young women [mean age, 21.0 years]), 1474 completed the study and data from 1377 were analyzed. At 4 weeks after the last dose, HPV antibody responses in girls and boys given 2 doses were noninferior to HPV antibody responses in adolescent girls and young women given 3 doses (P < .001 for each HPV type). Compared with adolescent girls and young women who received 3 doses over 6 months, the 1-sided 97.5% CIs for the ratio of HPV antibody geometric mean titers at 1 month after the last dose across the 9 HPV subtypes ranged from 1.36 to ∞ to 2.50 to ∞ for girls who received 2 doses 6 months apart; from 1.37 to ∞ to 2.55 to ∞ for boys who received 2 doses 6 months apart; and from 1.61 to ∞ to 5.36 to ∞ for girls and boys who received 2 doses 12 months apart. Conclusions and Relevance: Among girls and boys aged 9 to 14 years receiving 2-dose regimens of a 9-valent HPV vaccine separated by 6 or 12 months, immunogenicity 4 weeks after the last dose was noninferior to a 3-dose regimen in a cohort of adolescent girls and young women. Further research is needed to assess persistence of antibody responses and effects on clinical outcomes. Trial Registration: clinicaltrials.gov Identifier: NCT01984697.
Sujet(s)
Calendrier vaccinal , Infections à papillomavirus/prévention et contrôle , Vaccins contre les papillomavirus/administration et posologie , Vaccins contre les papillomavirus/immunologie , Adolescent , Adulte , Facteurs âges , Spécificité des anticorps , Enfant , Études de cohortes , Phénomènes physiologiques nutritionnels du sujet âgé , Femelle , Génotype , Humains , Immunogénicité des vaccins , Mâle , Papillomaviridae/génétique , Papillomaviridae/immunologie , Vaccins contre les papillomavirus/effets indésirables , Facteurs sexuels , Facteurs temps , Jeune adulteRÉSUMÉ
BACKGROUND: IGF-I is a useful tool in GH disorders diagnosis, however, the use of commercially available kits needs to be validated. OBJECTIVE: To validate the use of serum IGF-I concentrations measured by four immunoassays in the diagnosis of adult GH deficiency and acromegaly. DESIGN: Cross-sectional study. PATIENTS: Fifty GH-deficient (GHD) patients, 41 acromegaly patients and 405 controls. MEASUREMENTS: Serum IGF-I concentrations were measured by four commercial immunoassays: (1) RIA-NICHOLS; (2) ICMA-IMMULITE; (3) IRMA-IMMUNOTECH; and (4) non-extraction-IRMA-DSL. Reference values were established from the control population in six age groups. Individual results were transformed to standard deviation score (SD score) from the age-related reference population and reference data provided by each assay manufacturer. Diagnostic sensitivity for GH deficiency was calculated. RESULTS: IGF-I measured by the four assays differed significantly. In controls, assay 2 yielded the lowest results, followed by assays 1, 3 and 4 (P < 0.0001 for all comparisons). IGF-I declined with age, but no sex-related differences were observed. When IGF-I was standardized with respect to reference data obtained from the manufacturers, it showed better sensitivity in assays 1 and 2, than with our controls (65%vs. 77.5% and 58%vs. 70%, respectively) for GHD diagnosis. With assays 3 and 4, higher sensitivity was obtained when standardized with our controls (62%vs. 52% and 56%vs. 36%, respectively). In acromegaly, IGF-I was > 2 SD score with all assays. CONCLUSIONS: IGF-I SD score for GHD diagnosis differed according to the normative data used. All assays proved to be useful for active acromegaly diagnosis.
Sujet(s)
Acromégalie/sang , Hormone de croissance humaine/déficit , Dosage immunologique/méthodes , Facteur de croissance IGF-I/métabolisme , Acromégalie/métabolisme , Adolescent , Adulte , Répartition par âge , Sujet âgé , Études transversales , Femelle , Humains , Mâle , Adulte d'âge moyen , Reproductibilité des résultats , Sensibilité et spécificité , Caractères sexuels , Jeune adulteRÉSUMÉ
OBJECTIVE: GH1 gene presents a complex map of single nucleotide polymorphisms (SNPs) in the entire promoter, coding and noncoding regions. The aim of the study was to establish the complete map of GH1 gene SNPs in our control normal population and to analyse its association with adult height. DESIGN, SUBJECTS AND MEASUREMENTS: A systematic GH1 gene analysis was designed in a control population of 307 adults of both sexes with height normally distributed within normal range for the same population: -2 standard deviation scores (SDS) to +2 SDS. An analysis was performed on individual and combined genotype associations with adult height. RESULTS: Twenty-five SNPs presented a frequency over 1%: 11 in the promoter (P1 to P11), three in the 5'UTR region (P12 to P14), one in exon 1 (P15), three in intron 1 (P16 to P18), two in intron 2 (P19 and P20), two in exon 4 (P21 and P22) and three in intron 4 (P23 to P25). Twenty-nine additional changes with frequencies under 1% were found in 29 subjects. P8, P19, P20 and P25 had not been previously described. P6, P12, P17 and P25 accounted for 6.2% of the variation in adult height (P = 0.0007) in this population with genotypes A/G at P6, G/G at P6 and A/G at P12 decreasing height SDS (-0.063 +/- 0.031, -0.693 +/- 0.350 and -0.489 +/- 0.265, Mean +/- SE) and genotypes A/T at P17 and T/G at P25 increasing height SDS (+1.094 +/- 0.456 and +1.184 +/- 0.432). CONCLUSIONS: This study established the GH1 gene sequence variation map in a normal adult height control population confirming the high density of SNPs in a relatively small gene. Our study shows that the more frequent SNPs did not significantly contribute to height determination, while only one promoter and two intronic SNPs contributed significantly to it. Studies in larger populations will have to confirm the associations and in vitro functional studies will elucidate the mechanisms involved. Systematic GH1 gene analysis in patients with growth delay and suspected GH deficiency/insufficiency will clarify whether different SNP frequencies and/or the presence of different sequence changes may be associated with phenotypes in them.
Sujet(s)
Taille/génétique , Variation génétique , Hormone de croissance humaine/génétique , Polymorphisme de nucléotide simple , Adulte , Séquence nucléotidique , Loi du khi-deux , Amorces ADN/génétique , Femelle , Fréquence d'allèle , Génotype , Humains , Mâle , Données de séquences moléculaires , Réaction de polymérisation en chaîne/méthodes , Analyse de régression , Alignement de séquencesRÉSUMÉ
The pituitary-expressed GH1 gene was screened for mutation in a group of 74 children with familial short stature. Two novel mutations were identified: an Ile179Met substitution and a -360A-->G promoter variant. The Ile179Met variant was shown to exhibit a similar degree of resistance to proteolysis as wild-type GH, indicating that the introduction of Met does not cause significant misfolding. Secretion of Ile179Met GH from rat pituitary cells was also similar to that of wild type. Although receptor binding studies failed to show any difference in binding characteristics, molecular modeling studies suggested that the Ile179Met substitution might nevertheless perturb interactions between GH and the GH receptor loop containing the hotspot residue Trp169, thereby affecting signal transduction. The ability of the Ile179Met variant to activate a signal transducer and activator of transcription (STAT) 5-responsive luciferase reporter gene and induce phosphorylation of STAT 5 and ERK was therefore studied. In contrast to its ability to activate STAT 5 normally, activation of ERK by the Ile179Met variant was reduced to half that observed with wild type. Although differential effects on the activation of distinct signaling pathways by a mutant receptor agonist are unprecedented, these findings also suggest that the ERK pathway could play a role in mediating the action of GH.
Sujet(s)
Taille/génétique , Troubles de la croissance/génétique , Hormone de croissance humaine/génétique , Hormone de croissance humaine/métabolisme , Système de signalisation des MAP kinases/physiologie , Enfant , Cristallographie aux rayons X , Dépistage génétique , Troubles de la croissance/métabolisme , Hormone de croissance humaine/composition chimique , Humains , Mitogen-Activated Protein Kinases/métabolisme , Mutation ponctuelle , Régions promotrices (génétique)/génétique , Structure tertiaire des protéinesRÉSUMÉ
BACKGROUND AND OBJECTIVE: Deficiency of growth hormone (GH) in the adult is accompanied by changes in the body composition and a diminished health-related quality of life (HR-QoL). The aim of the study was to assess the biochemical response to GH replacement therapy and its safety as well as the resulting body composition and HR-QoL. PATIENTS AND METHODS: One hundred sixty-five patients with hypopituitarism and GH deficiency were studied. A double-blind,randomized, placebo-controlled, 6-months study was first designed,then followed by a further 6-months period in which all patients received GH. The initial GH dose was 0.125 IU/Kg/week followed by 0.250 IU/Kg/week. The body composition was determined by bioelectric impedanciometry and the HR-QoL was evaluated by the Nottingham Health Profile (NHP) and the QoL-AGHDA questionnaire. RESULTS: A significant increase in fat-free mass was observed during treatment with GH, which was accompanied with a simultaneous decrease in fat mass. Total body water increased during GH treatment. Energy and emotional reaction areas evaluated by the NHP showed changes at 6 months; no changes were observed in the remaining dimensions. A progressive improvement was observed in the QoL-AGHDA score in the treated group but not in the placebo group. Adverse events mainly consisted of fluid retention which resolved upon decrease of the dose. CONCLUSIONS: GH treatment in GH-deficient adults is in general well tolerated and leads to beneficial effects on body composition and HR-QoL.
Sujet(s)
Composition corporelle/effets des médicaments et des substances chimiques , Hormonothérapie substitutive/méthodes , Hormone de croissance humaine/déficit , Hormone de croissance humaine/usage thérapeutique , Hypopituitarisme/traitement médicamenteux , Qualité de vie , Adulte , Méthode en double aveugle , Femelle , Troubles de la croissance/traitement médicamenteux , Troubles de la croissance/étiologie , Humains , Mâle , Adulte d'âge moyen , Effet placebo , Enquêtes et questionnaires , Résultat thérapeutiqueRÉSUMÉ
FUNDAMENTO Y OBJETIVO: La deficiencia de hormona de crecimiento (GH) en el adulto se acompaña de alteraciones en la composición corporal y de una disminución de la calidad de vida relacionada con la salud (CVRS) que pueden ser revertidas mediante la administración de GH. El objetivo de este estudio fue valorar la respuesta bioquímica y sobre la composición corporal, así como la CVRS y la seguridad del tratamiento sustitutivo con GH. PACIENTES Y MÉTODO: Se estudió a 165 pacientes con hipopituitarismo y deficiencia de GH. El diseño fue de doble ciego, aleatorio, placebo-control durante un período de 6 meses, seguido de otros 6 en el que todos los pacientes recibieron GH. La dosis inicial fue de 0,125 UI/kg/semana, seguida de 0,25 UI/kg/semana. La composición corporal se determinó mediante impedanciometría bioeléctrica, y la CVRS se evaluó con los cuestionarios Perfil de Salud de Nottingham (PSN) y QoL-AGHDA. RESULTADOS: Las concentraciones de IGF-1 se incrementaron a los 6 meses en el grupo GH/GH pero no en el placebo/GH, y fueron normales para un grupo control de su mismo sexo y edad. Se observó un incremento significativo de la masa libre de grasa durante el tratamiento con GH y simultáneamente una disminución de la masa grasa. El agua corporal total presentó un aumento durante el tratamiento. A los 6 meses se produjeron cambios en las dimensiones de energía y reacción emocional en ambos grupos, valoradas con el PSN, sin apreciarse modificaciones en el resto de las dimensiones. Con el QoL-AGHDA se apreció una mejoría progresiva en la CVRS en el grupo tratado y no en el grupo placebo. Los efectos adversos se debieron fundamentalmente a retención hídrica y se resolvieron al disminuir las dosis. CONCLUSIONES: El tratamiento con GH en adultos con déficit de esta hormona fue generalmente bien tolerado y produjo efectos beneficiosos sobre la composición corporal y la CVRS (AU)
Sujet(s)
Adulte , Femelle , Mâle , Adulte d'âge moyen , Humains , Hypopituitarisme/traitement médicamenteux , Hormone de croissance humaine/déficit , Protéine-1 de liaison aux IGF/pharmacologie , Hypopituitarisme/étiologie , Études cas-témoins , Eau corporelle/métabolisme , Placebo/pharmacologie , Qualité de vie , Composition corporelle , Méthode en double aveugle , Protéine-1 de liaison aux IGF/administration et posologie , Protéine-1 de liaison aux IGF/effets indésirables , Protéine-1 de liaison aux IGF/métabolismeRÉSUMÉ
No disponible